(Q53224469)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

N Calvani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

F Morelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S Leo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

L Orlando

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

L Lombardi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A Gnoni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M Cinefra

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

V Lorusso

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S Cinieri

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

20 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1908-1913

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0048-0

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0048-0

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0048-0

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0048-0

Sequential sorafenib and sunitinib for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0048-0

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0048-0

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0048-0

Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0048-0

Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21858552

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Systemic therapy for renal cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21858552

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21858552

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-011-0048-0

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21858552%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference